drugset / Trial / NCT06334198
The Effect of Naldemedine on Opioid-induced Bowel Dysfunction
RandomizedCrossoverDouble-blindTreatment
Summary
Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain. Indeed, up to 90% of people on opioid treated patients experience constipation. Standard laxative treatment is often ineffective in opioid-induced constipation, but peripheral acting mu-receptor antagonists (PAMORAs) have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect. In this study, we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol
Timeline
- Start
- 2024-03-12
- Primary completion
- 2025-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Naldemedine | Other / unclassified | 0.2 mg | Oral |
| Comparator | Tramadol | Other / unclassified | 100 mg | Oral |